Cibus, Inc. (NASDAQ:CBUS) CFO Sells $24,629.10 in Stock

Cibus, Inc. (NASDAQ:CBUS) CFO Carlo Broos sold 4,647 shares of Cibus stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $5.30, for a total value of $24,629.10. Following the transaction, the chief financial officer now owns 74,197 shares in the company, valued at $393,244.10. This trade represents a 5.89 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Cibus Price Performance

Shares of CBUS opened at $4.53 on Friday. The firm has a market cap of $119.86 million, a P/E ratio of -0.20 and a beta of 1.79. Cibus, Inc. has a 1 year low of $2.86 and a 1 year high of $23.18. The company has a 50 day simple moving average of $4.03 and a two-hundred day simple moving average of $8.55.

Hedge Funds Weigh In On Cibus

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. SG Americas Securities LLC bought a new stake in Cibus in the third quarter worth $33,000. HighTower Advisors LLC raised its position in shares of Cibus by 20.6% during the 3rd quarter. HighTower Advisors LLC now owns 16,125 shares of the company’s stock valued at $52,000 after buying an additional 2,750 shares in the last quarter. Barclays PLC lifted its holdings in shares of Cibus by 287.2% in the 3rd quarter. Barclays PLC now owns 20,269 shares of the company’s stock valued at $66,000 after acquiring an additional 15,034 shares during the last quarter. Wellington Management Group LLP purchased a new position in Cibus in the third quarter worth about $111,000. Finally, Swan Global Investments LLC bought a new stake in Cibus during the third quarter worth approximately $115,000. Institutional investors own 33.81% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. Canaccord Genuity Group reiterated a “buy” rating and set a $20.00 price objective on shares of Cibus in a research note on Tuesday, October 22nd. Canaccord Genuity Group upgraded shares of Cibus to a “strong-buy” rating in a research report on Friday, July 19th. Alliance Global Partners lowered their target price on shares of Cibus from $25.00 to $23.50 and set a “buy” rating on the stock in a research note on Tuesday, September 24th. Finally, HC Wainwright reiterated a “buy” rating and issued a $25.00 price target on shares of Cibus in a research note on Monday, November 11th.

About Cibus

Cibus, Inc, a agricultural biotechnology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases.